We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Metastasis Requires Combined Effort of Several Genes

By Biotechdaily staff writers
Posted on 08 Jul 2003
Researchers looking into the problem of how cancer spreads within the body have found that metastasis of breast cancer into the bone marrow requires a specific subset of genes that are different from the genes responsible for the formation of the initial tumor.

Investigators at the Memorial Sloan-Kettering Cancer Center (New York, NY, USA; www.mskcc.org) worked with both a genetically engineered line of poorly metastatic mice tumor cells and with human breast cancer cells from a patient with metastatic disease. More...
In their study published in the June 2003 issue of Cancer Cell, they described a group of genes including interleukin-11 and CTGF (connective tissue growth factor) that encode osteolytic and angiogenic factors, which act cooperatively to cause osteolytic metastasis.

Senior author Dr. Joan Massagué, program chairman of cell biology at Memorial Sloan-Kettering, explained, "This means that the metastatic gene signature defines and forms a violent society, a large group of cells in a tumor that are competent to become metastatic cells. In and of themselves, these genes may not be mediators of metastases. Our finding is that above and beyond the genetic signature that has created this tumor, there is a toolbox of overexpressed genes that the cancer cell will need and that will be the mediators for the cell to thrive in the bone marrow.”




Related Links:
Memorial Sloan-Kettering Cancer Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Prefilled Tubes
Prefilled 5.0ml Tubes
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.